DeutschNewstral
Article
Hartford Courant on 2017-01-05 00:53
Alexion Finds Drug Sales Were Valid, Concerns Over Financial Reporting Controls
Related news
- Alexion Facing Class-Action Lawsuit Following InvestigationHartford Courant
- Jackson Lab Helping 11-Year-Old With Rare Disease In Search For CureHartford Courant
- DOT: CTfastrak Ridership Numbers Keep Climbing SteadilyHartford Courant
- Alexion Names New Chief ExecutiveHartford Courant
Why Alexion Pharmaceuticals Is OvervaluedForbes
CFO Moves: Alexion Pharmaceuticals, Chemring Groupblogs.wsj.com
Credit Suisse finds ‘material weaknesses’ in financial reporting controlsFinancial Times- Economists: It's Good CT Unemployment Rate Isn't Too LowHartford Courant
Alexion Names New CEO and CFOwsj.com- M20% of Big 4-audited IPOs report weaknesses in financial-reporting controlsmarketwatch.com
SEC’s High Priority Financial Reporting Cases Illustrate the Importance of Verifying and Maintaining Rigorous Internal Controlsjdsupra.com
Valid concerns over My NumberThe Japan Times
Alexion Pharma to pay $8.4B for Synageva BioPharmaseattletimes.com
Alexion Pharma to pay $8.4 billion for Synageva BioPharmadothaneagle.com
Letter: Neighbor concerns are validpasoroblesdailynews.com- VThree concerns with government financial reporting, says B.C.’s Auditor Generalvoiceonline.com
Alexion Pharmaceuticals announces new leadership appointmentswtnh.com
Sustainability reporting, financial reporting versus environmental reportingnewsday.co.zw- SFinancial reporting questionedstockandland.com.au
- PCounty financial reporting praisedplymouth-review.com